Category: Money tips Release Date: 2006-09-04
Source: Xiangcai Securities
Stock index continues to rise, the red a perfect ending in September, after October once again hit a stock index rose 32 points, broke through in April 2004 to 1783 points, the two cities can be combined volume of 450 million, the amount of red indicates the trend of price Chai Sing of October has been kicked off, while the disk dizzying variety of strong, banking, real estate, liquor, business, chemical fiber and other hot concept of things, but recently has been hovering at the bottom plate of medicine can be described as a meteoric rise, Sinopharm shares, nine Shido , Southwest Pharmaceutical have daily limit, medicine and signs of apparent outbreak of plate as a whole, afternoon cause for concern, as a leading anticancer drug research and development of pharmaceutical stocks Hisun Pharmaceutical (600,267) and is currently breaking into the early forms may focus on:
Company is one of the nation's largest chemical raw materials, but also to take advantage of the world's second patented technology to produce the U.S. Eli Lilly capreomycin company, which means that the company has entered, including WHO and other international cooperation in Space. VIVO with the United States entered into a collaboration venture capital funds in the future the United States VIVO is expected to bring new products and technologies into the sea are medicine, Vivo is currently investing more than 70 pharmaceutical companies have a large number of potential proprietary technology, pharmaceutical products, which will be the company enormous profit margins.
Company is recognized as a country the State Pharmaceutical Administration of antibiotics anticancer drug production base, more than 80% of chemical raw materials used for exports, its main product of cardiovascular drugs, anti-tumor margins were 60% higher than the same time, production of daunorubicin, doxorubicin, mitomycin C and other anti-tumor volume of exports of raw materials has occupied the U.S. generic drug market share of 60%, antiparasitic A Buddha STZ international veterinary drug market, accounting for 40 % or more of the share of cholesterol-lowering statin drug product production scale and technical level ranks second in the world, accounting for similar products in the world market, over 1 / 3 share. As the world's production of capreomycin, one of the few, the company has a clear monopoly industries and broad prospects.
The company already has 23 national second-class medicine, four new drugs 32, imitation or transplantation of species 51 to form a product gradient reserves, scientific research into the advantages of fast, the company has also applied for 18 technology patents, of which 13 have been preliminary qualified, two had entered a substantive review and publication of the application. R & D-based product advantages in the company's core competencies in the more true. Is also working with the United States pairs of health in modern medicine Technology Co., Ltd. joint venture, Hangzhou Hai Jian Pharmaceutical Technology Development Co., Ltd., engaged in cancer, cardiovascular disease, diabetes and other diseases closely related to a new generation of research and development of drugs and their preparations.
Because of the development prospects of the good, United States, social security, Bo, when large-scale involvement of institutions such as the strength at home and abroad, the recent share price at the bottom to obtain support, a strong significant breakthrough features, it is worth focusing on.
